RT Journal Article
SR Electronic
T1 Enhanced recovery after surgery in advanced ovarian cancer: a prospective randomized trial
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A33
OP A33
DO 10.1136/ijgc-2019-ESGO.33
VO 29
IS Suppl 4
A1 Sánchez-Iglesias, JL
A1 Carbonell Socias, M
A1 Pérez Benavente, A
A1 Gómez-Hidalgo, NR
A1 Manrique Muñoz, S
A1 García Gorriz, M
A1 Burgos Peláez, R
A1 Segurola Gurrutxaga, H
A1 Gutierrez Barceló, P
A1 Pérez Barragan, C
A1 Pamies Serrano, M
A1 Serrano Castro, S
A1 Scaillet Hopuberechts, AA
A1 Álvarez López, AM
A1 Monroy Parada, D
A1 Cossio Gil, Y
A1 Gil-Moreno, A
YR 2019
UL http://ijgc.bmj.com/content/29/Suppl_4/A33.1.abstract
AB Introduction/Background Enhanced recovery after surgery program (ERAS) had demonstrated to reduce hospitalizations without increasing the rate of complications. However, information on how to apply the program to advanced ovarian cancer patients is still limited. We postulate that the ERAS program improve the postoperatory recovery, decreasing the length of stay at hospital, the readmissions and medical cost-related.Methodology We designed the PROFAST trial (ClinicalTrials: NCT02172638) a prospective randomized trial. Patients diagnosed with ovarian carcinoma based on clinical or radiological suspicion and ovarian recurrences from 2014 to 2018 at Vall D’Hebron Hospital, were randomized to an specifically designed ERAS protocol or to a conventional management (CM). Reduction in the median length of stay was considered as a primary outcome. The incidence of perioperative complications and readmissions rated up to 28 days after surgery and medical cost-related were considered as secondary outcomes.Results 99 patients were included, 50 patients were randomized to the ERAS group, and 49 to the CM group. Demographic and clinical characteristics, stage at diagnoses and surgical procedures were similar in both groups with no statistically significant difference (p >0.005). The adherence to the ERAS program was >90% for all required items except for the needed of abdominal drainage. Median length of stay at hospital was 9 days vs 7 days, respectively (p<0.05). Readmission rates were highly reduced in theERAS group. There were not statistically significant difference in complication rates. The ERAS reduced the medical costs up to 13330 euros.Conclusion In the PROFAST trial, ERAS appears to be a safe and effective in reducing the median length of stay at hospital, readmission rates and medical- costs in advanced ovarian cancer surgery.Disclosure Nothing to disclose